As high DNA2 expression is also associated with resistance to chemotherapy in ovarian cancer (Fig. 1F), these data suggest that DNA2 inhibitors may be employed as a therapeutic strategy to overcome chemotherapy resistance in mutant p53-harboring cancers. This evidence concerns the gene TP53 and ovarian cancer.